Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ringsted, C.
Right arrow Articles by Qvist, J
Right arrow Search for Related Content
PubMed
Right arrow Articles by Ringsted, C.
Right arrow Articles by Qvist, J

Chest, Vol 96, 976-983, Copyright © 1989 by American College of Chest Physicians

ARTICLES

Ventilation-perfusion distributions and central hemodynamics in chronic obstructive pulmonary disease. Effects of terbutaline administration

CV Ringsted, K Eliasen, JB Andersen, L Heslet and J Qvist
Department of Anaesthesia and Intensive Care, Herlev Hospital, University of Copenhagen, Denmark.

We studied the effects of intravenous terbutaline on VA/Q distributions and central hemodynamics in 11 patients with mixed-type COPD. Terbutaline caused an increase in VA/Q inequality in patients having PaO2 values greater than 60 mm Hg which resulted in a moderate fall in the PaO2. Patients with PaO2 values less than 60 mm Hg, the highest mean PAPs and the poorest spirometric performances demonstrated no significant changes in VA/Q distributions or PaO2 after terbutaline. Cardiac output increased 40 to 60 percent in all patients after terbutaline with an increase in tissue oxygen delivery. Mean PAP did not change in any patient after terbutaline and pulmonary vasodilatation was indicated by a decrease of calculated static PVR. The decrease of PaO2 after terbutaline in COPD is related to a further deterioration of existing VA/Q relationships. The cause of these effects and lack of such responses in patients with more advanced disease are discussed.


This article has been cited by other articles:


Home page
 Eur Respir JHome page
J.A. Barbera, V.I. Peinado, and S. Santos
Pulmonary hypertension in chronic obstructive pulmonary disease
Eur. Respir. J., May 1, 2003; 21(5): 892 - 905.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
J. J. W. Liesker, P. J. Wijkstra, N. H. T. Ten Hacken, G. H. Koeter, D. S. Postma, and H. A. M. Kerstjens
A Systematic Review of the Effects of Bronchodilators on Exercise Capacity in Patients With COPD
Chest, February 1, 2002; 121(2): 597 - 608.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1989 by the American College of Chest Physicians.